Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 45

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 45
---
 |      103,799 |
| Add Fair Value of Awards Granted and Vested in 2023 as of the Vesting Date                               |     |    35,158 |     |       13,068 |
| Add Change in Fair Value of Awards Granted in Prior Years that Vested during 2023 as of the Vesting Date |     |   236,036 |     |      163,464 |
| Total Compensation Actually Paid                                                                         |     | 1,572,904 |     |    1,581,624 |

26

TABLE OF CONTENTS

| 2022                                                                                                     |     |       CEO |     | Non-CEO NEOs |
| SCT Total Compensation                                                                                   |     |   954,651 |     |    1,083,987 |
| Add Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/22                        |     |   449,783 |     |      359,663 |
| Add Change in Fair Value of Awards Granted in Prior Years that Vested during 2022 as of the Vesting Date |     |   236,039 |     |      167,207 |
| Total Compensation Actually Paid                                                                         |     | 1,640,473 |     |    1,610,857 |

Pay Versus Performance Narrative Disclosure In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table on CAP and each of total shareholder return (“TSR”) and net loss. We do not utilize TSR and net loss in our executive compensation program. However, we do utilize several other performance measures to align executive compensation with our performance. As described in more detail above in the section “Annual Bonuses and Non-Equity Incentive Plan Compensation,” part of the compensation our NEOs are eligible to receive consists of annual performance-based cash bonuses that are designed to provide our executives appropriate incentives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these goals, subject to certain employment criteria. Additionally, we view stock options, which are an integral part of our executive compensation program, as related to company performance although not directly tied to TSR, because they provide value only if the market price of our Common Stock increases, and if the executive officer continues in our employment over the vesting period. These stock option awards strongly align our executive officers’ interests with those of our stockholders by